Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jun 1;31(6):382-391.
doi: 10.1097/IJG.0000000000002030. Epub 2022 Apr 6.

A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study

Thomas R Walters  1 , Angela C Kothe  2 , José L Boyer  3 , Dale W Usner  4 , Krisol Lopez  3 , Brigitte Duquesroix  5 , Robert D Fechtner  6 , Tomas Navratil  3
Affiliations
Randomized Controlled Trial

A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study

Thomas R Walters et al. J Glaucoma. .

Abstract

Prcis: NCX 470 0.042% and 0.065% were statistically superior in intraocular pressure (IOP) lowering to latanoprost 0.005%, and NCX 470 0.021% was noninferior. All NCX 470 concentrations were safe and well tolerated.

Purpose: The purpose of this study was to compare varying concentrations of NCX 470 (a nitric oxide-donating bimatoprost) to latanoprost in a dose-response safety and efficacy trial.

Patients and methods: Adult patients with bilateral open-angle glaucoma or ocular hypertension were randomized to NCX 470 0.021% (n=111), 0.042% (n=108), 0.065% (n=107), or latanoprost 0.005% (n=107) once daily in the evening. IOP was measured at 8:00 am, 10:00 am, and 4:00 pm at weeks 1, 2, and 4. The primary efficacy endpoint was the reduction from baseline in mean diurnal IOP at week 4. Secondary efficacy endpoints included reductions from baseline in mean diurnal IOP at weeks 1 and 2, and reductions from baseline in time-matched IOP at 8:00 am, 10:00 am, and 4:00 pm at weeks 1, 2, and 4. Adverse events were evaluated.

Results: All concentrations of NCX 470 resulted in significant reductions of mean diurnal IOP. The 0.042% and 0.065% concentrations were statistically superior to latanoprost 0.005%, and 0.021% was noninferior to latanoprost for change from baseline in mean diurnal IOP at week 4. The 0.065% concentration was also superior to latanoprost by up to 1.4 mm Hg for reduction from baseline at 8:00 am, 10:00 am, and 4:00 pm at week 4. NCX 470 was safe and well tolerated; conjunctival hyperemia was the most frequently reported adverse event.

Conclusions: NCX 470 demonstrated dose-dependent reductions in IOP. The 0.042% and 0.065% concentrations demonstrated significantly greater reductions from baseline in mean diurnal IOP than latanoprost 0.005% at week 4, suggesting that higher concentrations may show even greater efficacy.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Chemical structure of NCX 470.
FIGURE 2
FIGURE 2
Reduction from baseline in mean diurnal intraocular pressure (IOP) at week 4 for NCX 470 (0.021%, 0.042%, and 0.065%) and latanoprost (±SE; intent-to-treat population). *Statistically significantly greater IOP reductions compared with latanoprost (P<0.05).
FIGURE 3
FIGURE 3
Mean intraocular pressure (IOP) reduction from baseline for NCX 470 0.065% and latanoprost at 8:00 am, 10:00 am, and 4:00 pm at weeks 1, 2, and 4 (±SE; intent-to-treat population). *Statistically significantly greater IOP reduction compared with latanoprost (P<0.05).
See this image and copyright information in PMC

References

    1. Jonas JB, Aung T, Bourne RR, et al. . Glaucoma. Lancet. 2017;309:2183–2193. - PubMed
    1. Tham YC, Li X, Wong TY, et al. . Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090. - PubMed
    1. Leske MC, Heijl A, Hussein M, et al. . Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48–56. - PubMed
    1. Daka Q, Trkulja V. Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews. Croat Med J. 2014;55:468–480. - PMC - PubMed
    1. Noecker RS, Dirks MS, Choplin NT, et al. . A six-month randomized clinical trial comparing the intraocular pressure lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55–63. - PubMed

Publication types